Repligen completes acquisition of BioLife Solutions in cash-and-stock deal

Bitget2026/10/06 13:06

Repligen completed its acquisition of BioLife Solutions, expanding its cell and gene therapy tools footprint. BioLife holders received USD 11.25 per share in cash, plus 0.1442 shares of Repligen stock. Repligen plans to outline the deal’s expected effect on its 2026 financial outlook on its Q3 2026 earnings call. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repligen Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060905PRIMZONEFULLFEED9840481) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.